Business context and reporting period
Cellectar Biosciences, Inc. filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2016. It is a clinical-stage biopharmaceutical company developing cancer-targeting phospholipid drug conjugates (PDCs); it reported no product revenue and remains dependent on external financing.
Its lead candidate, CLR 131, was in a Phase 1 study for relapsed or refractory multiple myeloma. After reviewing Cohort 2 data in September, the data monitoring committee supported a 33% dose increase and enrollment in Cohort 3. A $2.0 million NCI grant was awarded to advance CLR 131; management planned to start a Phase 2 study in the first quarter of 2017.
Financial results and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development | $1.306 million | $1.168 million | $3.310 million | $4.195 million |
| General and administrative | $1.162 million | $0.835 million | $3.491 million | $2.596 million |
| Restructuring costs | None | $0.090 million | None | $0.180 million |
| Operating loss | $2.468 million | $2.093 million | $6.802 million | $6.971 million |
| Net loss | $2.287 million | $1.858 million | $3.595 million | $6.446 million |
| Net loss per share | $0.43 | $2.46 | $1.02 | $8.53 |
| Cash used in operating activities | Not separately stated for the quarter | Not separately stated for the quarter | $5.933 million | $6.719 million |
At September 30, 2016, cash and cash equivalents were $5.646 million, versus $3.858 million at December 31, 2015; restricted cash was $55,000. Total current assets were $6.139 million and current liabilities $1.426 million. Total liabilities were $1.579 million, including $147,939 of current notes payable; there were no long-term notes payable. Stockholders’ equity was $7.717 million.
Cash increased by $1.788 million over the nine-month period, largely reflecting $7.371 million of proceeds from common-stock issuance and $652,516 from warrant exercises, offset by operating cash use and debt payments. Cash flow from operations was affected by a $3.201 million noncash gain on revaluation of derivative warrants. The filing reports no gross margin; product revenue was not reported.
Material changes and unusual items
- For the first nine months, R&D expense fell 21% year over year, mainly due to lower personnel, trial-related materials and services, and facility costs. G&A rose 34%, driven by consulting and professional fees, investor relations, personnel, and public-company costs.
- Nine-month net loss improved year over year, substantially reflecting the $3.201 million derivative-warrant revaluation gain, compared with a $526,000 gain in 2015. This accounting gain was noncash; the operating loss remained $6.802 million.
- The April 2016 underwritten offering generated approximately $8.0 million gross and $7.2 million net proceeds. A March 2016 1-for-10 reverse stock split was followed by a common-stock offering and substantial warrant issuance. Common shares outstanding increased from 858,140 at year-end 2015 to 5,368,235 at September 30, 2016; additional warrants and options could dilute shareholders.
- The company reported a $187,650 derivative-warrant liability at September 30, down from $4.781 million at year-end 2015. Changes reflected warrant revaluation, exercises, and amendments that caused certain warrants to be reclassified to equity.
Outlook, risks and contingencies
Management said the September cash balance was expected to fund operations into the first quarter of 2017, but that continued operations beyond then depended on additional financing, a strategic transaction, or other funding. The company expected operating losses to continue and said it had not entered negotiations for a financing transaction. It cautioned that funding might not be available on acceptable terms or when needed; failure to obtain it could force delays, reductions, or termination of programs or require licensing rights to third parties.
Key development and regulatory uncertainties include clinical-trial outcomes, funding needs, manufacturing, and regulatory approval. The FDA determined CLR 1502 should be evaluated as a combination product and required a new investigational application before a Phase 1 study; the company was assessing its development path. The company also cited competition, dependence on key personnel, and the possibility that candidates will fail or never generate revenue. No material impact from ordinary-course legal matters was anticipated, and no legal proceedings were reported.
Disclosure controls and internal control over financial reporting were deemed ineffective as of September 30, 2016 because of an unremediated material weakness involving complex accounting and limited resources. Management said the financial statements were fairly stated in all material respects and described plans to improve technical accounting resources and consultation, but gave no assurance those actions would resolve the weakness.
Important facts for investors to verify
- Whether new financing or a strategic transaction was secured before the stated cash runway into Q1 2017 expired, and the resulting cash runway and dilution.
- CLR 131 enrollment, safety and efficacy progress, and whether the planned Phase 2 study began as expected.
- Progress on remediation of the material weakness and effectiveness of disclosure and financial-reporting controls.
- The potential dilution and accounting effects of outstanding warrants and options, including warrant exercises and derivative remeasurement.
- Whether CLR 1502’s revised regulatory pathway or other clinical and regulatory developments changed program timing, costs, or prospects.